[HTML][HTML] A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19

H Mashayekhi-Sardoo, H Hosseinjani - Journal of Basic and Clinical …, 2022 - degruyter.com
Abstract Since December 2019, the COVID-19 emerging pandemic caused by SARS-CoV-2
has resulted in one of the most important global health threats. Concerning the absence of …

[PDF][PDF] The mTOR pathway as a target for SARS-COV-2: Rapamycin as a possible alternative pharmacological therapeutic for COVID-19

LB Teixeira, WC Santos - Act Farma Terap, 2020 - socesfar.es
The number of deceased individuals from COVID-19 has been exponentially increasing all
over the world. The pandemic proves to be devastating and, therefore, there is an urgent …

mTOR inhibition: a double-edged sword in patients with COVID-19?

M Ghasemnejad-Berenji - Human Cell, 2021 - Springer
The current COVID-19 is one of the deadliest pandemics in recent decades. In the lack of a
specific treatment for this novel infection, knowing the role of cell signaling pathways in the …

Can we use mTOR inhibitors for COVID-19 therapy?

IY Aneva, S Habtemariam, M Banach… - … Chemistry & High …, 2022 - ingentaconnect.com
Infection by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) provokes
acute inflammation due to extensive replication of the virus in the epithelial cells of the upper …

[PDF][PDF] mTOR: A possible therapeutic target against SARS-CoV-2 infection

N Khan - Arch Stem Cell Ther, 2021 - probiologists.com
The recent pandemic of SARS-CoV-2 has emerged as a health emergency to develop
effective therapeutic strategies for restricting deadly disease, COVID-19. SARS-CoV-2 …

[HTML][HTML] A review on Coronavirus Disease and potentially active drugs targeting Coronavirus

T Verma, M Sinha, B Nitin, SR Yadav… - Biomedical and …, 2021 - journals.lww.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus with single
positive-strand RNA, having glycoproteins projection on envelopes so reveals a halo-like …

[HTML][HTML] Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential

O Kamyshnyi, V Matskevych, T Lenchuk… - Biomedicine & …, 2021 - Elsevier
The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has become a serious
challenge for medicine and science. Analysis of the molecular mechanisms associated with …

Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19

A Husain, SN Byrareddy - Chemico-biological interactions, 2020 - Elsevier
The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of
Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic …

[HTML][HTML] An open question: is it rational to inhibit the mTor-dependent pathway as COVID-19 therapy?

G Terrazzano, V Rubino, AT Palatucci… - Frontiers in …, 2020 - frontiersin.org
In December 2019, a novel coronavirus infection appeared in China (Wuhan City and Hubei
Province), causing the first cases of abnormal severe pneumonia. Since then, the SARS …

Triamcinolone as a Potential Inhibitor of SARS-CoV-2 Main Protease and Cytokine Storm: An In silico Study

A Mishra, F Abul Qais, Y Pathak… - Letters in Drug …, 2023 - ingentaconnect.com
Background: An ongoing global public health concern is the emerging COVID-19 pandemic
triggered by acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Mpro, a main …